Serial #90741545
DEAD

Serial Number

90741545

Owner

AMBRY GENETICS CORPORATION

Attorney

Carrie L. Kiedrowski

Filing Date

May 28, 2021

Add to watchlist:

No watchlists yet
View on USPTO

Serial #90741545 Trademark

Serial Number: 90741545

Serial #90741545 is a trademark filed by AMBRY GENETICS CORPORATION on May 28, 2021. The trademark is classified under Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

AMBRY GENETICS CORPORATION (126 trademarks)

1 Enterprise
Aliso Viejo, CA 92656

Entity Type: 03

Trademark Details

Filing Date

May 28, 2021

Registration Date

Not Registered

Published for Opposition

June 28, 2022

Goods & Services

Providing genomic, imaging and pathology data being medical information and medical analyses based on collected clinical and research information in the field of cancer and other diseases for medical purposes; analysis of cells, tissues, gene expressions, gene sequences, genome annotation, transcriptome characterization, and genome mapping for medical diagnosis and treatment of cancer, neurological disease, respiratory disease, inflammatory disease, and mitochondrial disease; preparation of reports relating to gene expressions, gene and genome sequences, genome interaction and annotation, transcriptome analysis and characterization, and genome mapping for medical diagnosis and treatment of cancer, neurological disease, respiratory disease, inflammatory disease, and mitochondrial disease; medical assistance services in the nature of genetic and medical information provided to medical professionals from remote locations via the internet and global computer networks through the use of archived genome sequence information, medical images, diagnostic test results, and a data storage and retrieval system; medical genetic testing consultations provided via phone, online chat or videoconferencing; medical diagnostic testing, monitoring and reporting services; medical imaging services; medical information; medical screening; medical testing for diagnostic purposes; multi-disciplinary, integrative, genetic consultations for medical treatment purposes; providing a website featuring genetic and medical information; providing an internet website for medical professionals and medical patients featuring medical information from remote locations via devices that feed information to the website that is processed, exchanged and accessed in real-time by users; providing an internet website for medical professionals and medical patients featuring medical information from remote locations via electronic patient monitoring devices that feed information to the website that can be accessed in real-time by medical professionals for purposes of monitoring and diagnosing medical conditions; providing medical profiles and medical record analysis and assessments via a website that are designed to provide custom tailored outputs about recommended resources and treatments associated with a defined set of symptoms, concerns, genome sequencing analysis, microbiome sequencing analysis, metabolome analysis, advanced clinical imaging, laboratory tests, and medical imaging and DNA screening; providing medical testing and medical consultations to individuals and their physicians to help them make health, wellness and nutritional changes in their daily living to improve health; providing on-line medical record analysis services designed to provide patients with custom tailored information about the range of possible diagnoses and therapies associated with a defined set of symptoms based on genome sequencing analysis, microbiome sequencing analysis, metabolome analysis, advanced clinical imaging, laboratory tests, and medical imaging and DNA screening; provision of health care and medical services by health care professionals via the internet or telecommunication networks; remote monitoring of data indicative of the health or condition of an individual or group of individuals for medical diagnosis and treatment purposes; health assessment services, namely, providing assessment of risk of disease and providing health monitoring of individuals all through use of genome sequencing analysis and reporting, microbiome sequencing analysis, metabolome analysis, advanced clinical imaging, laboratory tests, and medical imaging and DNA screening; all for medical treatment and diagnostic purposes

Cloud computing featuring software for analyzing genomic, imaging, pathology and clinical data; consulting services relating to scientific and medical research concerning genomic, imaging, pathology and clinical data; providing temporary use of non-downloadable computer software for hosting, managing, sharing, transmitting, and analyzing patient genomic, imaging, pathology and clinical data to improve the quality of medical diagnosis, care, and outcome; design, development, computer programming, testing, maintenance, customization, and operation of computer software in clinical trials or studies; designing clinical trials or studies, enriching and enhancing clinical trial or study designs in the nature of research and development in the field of medicine; clinical research in the fields of de-risking clinical trial or study designs, clinical trials simulations and clinical endpoint selection; clinical research, namely, analyzing non-clinical data, preclinical data, and clinical data, analyzing results of clinical trials or studies, and evaluating clinical outcomes and treatment responses; providing scientific analysis in the field of next generation sequencing (NGS), namely, the analysis and interpretation of genomic, imaging, pathology and clinical data; medical and scientific research, namely, conducting laboratory testing for clinical trials of pharmaceuticals and medical devices in humans; health care services, namely, medical laboratory services and clinical scientific laboratory services for testing clinical specimens for the purpose of providing information for medical research, clinical trials, and pre-clinical investigations; providing a website featuring temporary use of non-downloadable software for clinical and safety information management, process facilitation for clinical endpoint adjudication, electronic data capture of member voting, efficient case packaging and automated databasing of voting and decision data for use in pharmaceutical or medical device clinical trials; clinical research in the fields of patient identification and a priori responder selection, individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination, selection, and identification, drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses, omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses; clinical research, namely, accessing and analyzing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, and in the medical field, biomedical field, healthcare field, pharmaceutical field, and biotechnological field using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulation; consulting, consultancy, and consulting services related to clinical trials or studies, namely, designing clinical trials or studies, enriching and enhancing clinical trial or study designs in the nature of research and development in the field of medicine, de-risking clinical trial or study designs, conducting clinical trials simulations, clinical endpoint selection, analyzing preclinical data, and clinical data, analyzing results of clinical trials or studies, and evaluating clinical outcomes and treatment responses; consulting, consultancy, and consulting services related to clinical trials or studies, namely, conducting patient identification and a priori responder selection, individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination; conducting drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses in the nature of medical research, and pharmaceutical development, in the fields of omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses, and accessing, processing, and analyzing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, all related to the medical field, biomedical field, healthcare field, pharmaceutical field, and biotechnological field using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulation; medical research in the nature of disease diagnoses and treatment determination, selection, and identification of cells, proteins, small molecules, and nucleotides in a sample for scientific, research, and technological purposes, drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses, omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses, and accessing, processing, and analyzing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, and services all in the medical field, biomedical field, healthcare field, pharmaceutical field, and biotechnological field using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulation for others; platform as a service (PaaS) featuring computer software platforms for hosting, managing, sharing, transmitting, and analyzing patient genomic, imaging, pathology and clinical data to improve the quality of medical diagnosis, care, and outcome; all of the foregoing in the field of clinical care, medical diagnostic, and scientific research services; platform as a service (PaaS) featuring computer software platforms for providing clinical decision support for patient care; platform as a service (PaaS) featuring computer platforms and software for using artificial intelligence for machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics for the analysis of cells, tissues, gene expression, gene sequences, genome annotation, transcriptome characterization and genome mapping for the purpose of medical research, and pharmaceutical development; platform as a service (PaaS) featuring computer platforms and software for using artificial intelligence for precision medicine, bioinformatics, modeling, and simulation in clinical trials or studies, designing clinical trials or studies, enriching and enhancing clinical trial or study designs in the nature of research and development in the field of medicine, de-risking clinical trial or study designs, clinical trials simulations, clinical endpoint selection, analyzing non-clinical data, preclinical data, and clinical data, analyzing results of clinical trials or studies, and evaluating clinical outcomes and treatment responses, patient identification and a priori responder selection, individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination, selection, and identification, drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses, omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses, and accessing, processing, and analyzing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, all in the medical field, biomedical field, healthcare field, pharmaceutical field, and biotechnological field; software as a service (SaaS) services featuring software for use in medical diagnostics, medical image analysis, medical screening, medical testing, DNA screening for medical purposes, and genetic testing for medical purposes; software as a service (SaaS) services featuring software for the analysis of medical data, namely, genomic, imaging, pathology and clinical data for use in the prevention, diagnosis and treatment of medical conditions, analyzing clinical trials, analyzing drug interactions, development of vaccines and medicines, analyzing medical diagnostic data, analyzing molecular medicine data, analyzing precision medicine data, and structural and functional analysis of genomes; software as a service (SaaS) services featuring software for the analysis of genomic data for use in tracking variation and mutation of pathogens; software as a service (SaaS) services featuring software for determining and predicting patterns in data, namely, medical data, genomic data, proteomic data, metabolomics data, transcriptomic data, nutritional and nutrigenomics data, medical imaging data, health care data, health records, medical records, genomic data, and environmental factor data; software as a service (SaaS) services featuring software for executing preconfigured non-field specific machine learning and deep learning algorithms and processes for the purposes of uploading and managing data for the training of preconfigured data models implemented on a hosted software platform utilizing said machine learning and deep learning processes and for utilizing said trained data models for use in medical diagnostics, medical image analysis, medical screening, medical testing, DNA screening for medical purposes, and genetic testing for medical purposes; software as a service (SaaS) services featuring software for conducting natural language processing on medical records to transform unstructured data into structured data supporting clinical and research use; software as a service (SaaS) featuring computer platforms for using artificial intelligence for determination, selection, and identification, drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses, omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses, and accessing, processing, and analyzing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, all in the medical field, biomedical field, healthcare field, pharmaceutical field, and biotechnological field

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Mar 25, 2024 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Mar 25, 2024 ABN6
ASSIGNED TO EXAMINER
Oct 26, 2023 DOCK
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 15, 2023 EXRA
SOU EXTENSION 2 GRANTED
Jun 13, 2023 EX2G
SOU EXTENSION 2 FILED
Jun 13, 2023 EXT2
SOU TEAS EXTENSION RECEIVED
Jun 13, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 26, 2023 EXRA
SOU EXTENSION 1 GRANTED
Jan 24, 2023 EX1G
SOU EXTENSION 1 FILED
Jan 24, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Jan 24, 2023 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 23, 2022 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 28, 2022 NPUB
PUBLISHED FOR OPPOSITION
Jun 28, 2022 PUBO
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Jun 23, 2022 ASCK
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 8, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 25, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
May 25, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
May 25, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
May 25, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
May 25, 2022 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
May 9, 2022 GNFN
FINAL REFUSAL E-MAILED
May 9, 2022 GNFR
FINAL REFUSAL WRITTEN
May 9, 2022 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 5, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 4, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 4, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 7, 2021 GNRN
NON-FINAL ACTION E-MAILED
Oct 7, 2021 GNRT
NON-FINAL ACTION WRITTEN
Oct 7, 2021 CNRT
ASSIGNED TO EXAMINER
Oct 6, 2021 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Aug 24, 2021 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 23, 2021 NWOS
NEW APPLICATION ENTERED
Jun 1, 2021 NWAP